Answers are grounded in this paper and cite their sources.
Chemical process study demonstrates scalable synthesis of the enlicitide decanoate Northern Fragment, highlighting efficient multi-kilogram manufacturing for oral PCSK9 inhibitors.
Here we report the development of a large-scale manufacturing process for the synthesis of the Northern Fragment of enlicitide decanoate (MK-0616), an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). The key topics covered are (1) process development for the selective tryptophan allylation; (2) development of the one-pot process for two consecutive peptide coupling reactions; (3) process development for the one-pot cleavage of two N - tert -butyloxycarbonyl ( N -Boc) groups and a tert -butyl ester; and (4) process development of the magnesium chloride (MgCl 2 )-mediated selective macrolactamization. This optimized process was demonstrated to produce the key fragment at >150 kg scale per batch in the synthesis of enlicitide.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: